Dynavax Technologies Corporation has reported its financial results for the first quarter of 2025, highlighting a significant increase in revenue and market share. Total revenue reached $68.2 million, marking a 34% rise compared to $50.8 million in the same quarter of 2024. The net product revenue for HEPLISAV-B® was $65 million, representing a 36% increase from $47.8 million in the previous year's first quarter. The company's HEPLISAV-B® total estimated U.S. market share also grew to approximately 43%, up from about 41% in Q1 2024. Adjusted EBITDA improved to negative $4 million, compared to negative $7 million in Q1 2024, with expectations for Adjusted EBITDA to reach at least $75 million by the end of 2025. Dynavax has executed over 85% of its $200 million share repurchase program, with $172 million completed as of May 5, 2025. The company continues to advance its vaccine pipeline, leveraging its proprietary CpG 1018 adjuvant, and has announced new pipeline programs alongside their ongoing shingles and plague vaccine initiatives.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.